| 有应用前景,但任重道远——评靶向CD3和CD123双特异性抗体flotetuzumab在复发/难治AML中的研究 |
| |
| 引用本文： | 徐开林,朱锋,王惊华.有应用前景,但任重道远——评靶向CD3和CD123双特异性抗体flotetuzumab在复发/难治AML中的研究[J].循证医学,2022,22(2):95-97. |
| |
| 作者姓名： | 徐开林 朱锋 王惊华 |
| |
| 作者单位： | 1.徐州医科大学附属医院血液科, 江苏徐州 221004; 2.广东省人民医院血液科、广东省医学科学院, 广州 510080 |
| |
| 摘 要： |
|
| 关 键 词： | 急性髓系白血病 flotetuzumab 复发难治性 |
A Promising Application Prospect,but It Still Has a Long Way to Go： Review on the Study of the Bispecific Antibody Flotetuzumab Targeting CD3 and CD123 in Relapsed/Refractory AML |
| |
| XU Kai-lin,ZHU Feng,WANG Jing-hua.A Promising Application Prospect,but It Still Has a Long Way to Go： Review on the Study of the Bispecific Antibody Flotetuzumab Targeting CD3 and CD123 in Relapsed/Refractory AML[J].The Journal of Evidence-Based Medicine,2022,22(2):95-97. |
| |
| Authors: | XU Kai-lin ZHU Feng WANG Jing-hua |
| |
| Institution: | Reviewers' address： Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Jiangsu Xuzhou 221004, China |
| |
| Abstract: | |
| |
| Keywords: | acute myeloid leukemia flotetuzumab refractory and relapsed |
|
| 点击此处可从《循证医学》浏览原始摘要信息 |
| 点击此处可从《循证医学》下载免费的PDF全文 |
